Stock · IQV · Healthcare
United States · Large Cap · listed since 2013 · Revenue 12 mo. $17B
Price as of 11/06/2026
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Original text from the data provider
Summary
47.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €1.8B (2025), it supports €20.5B. The remaining €21.1B of the market value assume it grows 9.9% a year for 10 years and not at all afterwards.
Required FCF growth per year
9.9%
no growth afterwards
Price to operating cash flow 16.3×, within its usual range.
Middle half of 20 quarters: 12.7× to 17.8×, median 16.5×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
8 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, FCF margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 20.91% | 11.52% | Rank 78 |
| Return on capital (Greenblatt) | 265.13% | 32.55% | Rank 98 |
| EBIT margin | 13.38% | 18.31% | Rank 35 |
| FCF margin | 12.58% | 14.12% | Rank 42 |
| Gross margin | 33.29% | 60.99% | Rank 20 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 5.87% | 8.04% | Rank 38 |
| Earnings growth, 3 years per year | 11.05% | 5.44% | Rank 62 |
| Earnings growth, 5 years per year | 40.52% | 7.00% | Rank 96 |
| Sustainable growth (ROE × retained earnings) | 3.70% | 3.66% | Rank 50 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.88% | 2.90% | Rank 49 |
| FCF yield | 4.43% | 3.63% | Rank 61 |
| EV/saleslower is better | 3.70 | 4.03 | Rank 52 |
| EV/EBITlower is better | 27.67 | 21.73 | Rank 34 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 19.31% | 8.66% | Rank 64 |
| Share price, 6 months | 52.59% | 24.27% | Rank 90 |
| Share price, 3 months | 19.01% | 15.42% | Rank 62 |
| Distance from 52-week high | −2.70% | −7.35% | Rank 72 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 3.56% | 0.30% | Rank 23 |
| Change in share countlower is better | −5.40% | 0.00% | Rank 95 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −1.41% | 0.05% | Rank 31 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 21.72% | 48.40% | Rank 10 |
| Net debt/EBITDAlower is better | 4.78 | 1.11 | Rank 3 |
| Debt to equitylower is better | 2.49 | 0.48 | Rank 5 |
| Volatility, 1 yearlower is better | 40.51% | 31.42% | Rank 22 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 6.8 | 9.4% | $696.0M | 152M | 6.0 |
| 2017 | 9.7 | 7.4% | $601.0M | 223M | 9.3 |
| 2018 | 10.4 | 7.1% | $795.0M | 208M | 10.1 |
| 2019 | 11.1 | 7.0% | $835.0M | 200M | 11.2 |
| 2020 | 11.4 | 6.4% | $1.3B | 195M | 11.1 |
| 2021 | 13.9 | 10.0% | $2.3B | 195M | 11.1 |
| 2022 | 14.4 | 12.5% | $1.6B | 191M | 11.8 |
| 2023 | 15.0 | 13.2% | $1.5B | 186M | 12.5 |
| 2024 | 15.4 | 14.3% | $2.1B | 183M | 12.5 |
| 2025 | 16.3 | 13.4% | $2.1B | 174M | 14.2 |
3 of 7 StockScorer Score rules met · How the score is built
IQVIA Holdings Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
IQVIA Holdings Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for IQVIA Holdings Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 34.7 | 30.0 |
| P/B ratio | 7.3 | 4.8 |
| Return on equity (ROE) | 20.9% | 11.5% |
| Equity ratio | 21.7% | 48.4% |
| Debt-to-equity (D/E) | 2.49 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| IQV | IQVIA Holdings Incthis page | |
| WAT | Waters Corporation | Low4.5 |
| NTRA | Natera Inc | locked |
| IDXX | IDEXX Laboratories Inc | Medium5.5 |
| A | Agilent Technologies Inc | locked |
| ILMN | Illumina Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.